- Anthem has decided to cover Veracyte's (NASDAQ:VCYT +2%) Afirma Gene Expression Classifier for use in the diagnosis of thyroid cancer for its 40M members. The test identifies patients with benign thyroid nodules whose biopsy results are indeterminate, thereby enabling them to avoid diagnostic surgery.
Anthem to cover Veracyte's thyroid cancer test; shares up 2%
Recommended For You
More Trending News
About VCYT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VCYT | - | - |
Veracyte, Inc. |